NCT00928187 - Evaluation of Three Strategies of Second-line Antiretroviral Treatment in Africa (Dakar - Bobo-Dioulasso - Yaoundé) | Biotech Hunter

Enrollment

454

Participants

Timeline

Start Date

November 30, 2009

Primary Completion Date

September 30, 2013

Study Completion Date

December 31, 2015

Conditions

HIVHIV Infections

Interventions

DRUG

emtricitabine/tenofovir + lopinavir/ritonavir (WHO recommended second line)

Emtricitabine 200 mg/tenofovir 300 mg 1 tablet/day with food + Lopinavir 200 mg/Ritonavir 50 mg 2 tablets in the morning and 2 tablets in the evening

DRUG

abacavir + didanosine + lopinavir/ritonavir (WHO recommended second line)

Didanosine 1 entero-coated capsule/day in fasting conditions (dosage 250 mg if weight \< 60 kg, 400 mg if weight \> 60 kg) + abacavir 300 mg 1 tablet in the morning and in the evening + Lopinavir 200 mg/Ritonavir 50 mg 2 tablets morning and evening

DRUG

emtricitabine/tenofovir + darunavir + ritonavir (Second line strategy under evaluation)

Emtricitabine 200 mg/tenofovir 300 mg 1 tablet/day with food + darunavir 400 mg 2 tablets + ritonavir 100 mg 1 capsule, in a single dose with food

Trial Locations (3)

Unknown

Day Hospital, CHU Sanou Souro, Bobo-Dioulasso

Day Hospital, Central Hospital, Yaoundé

Clinical Research and Training Center, Fann Hospital, Dakar